FREE STANDARD SHIPPING ON ORDERS $250+

IGF-1 LR3

From $38.40

Shop

IGF-1 LR3 · Research brief

IGF-1 LR3 Blood Work Labs Check Before After | Real Peptides

RP
Real Peptides Research TeamEditorial
Updated May 4, 20269 min read
56 WORDS

Short answer

Most researchers skip the blood work that matters most. Baseline IGF-1 levels. Without that number, you're administering IGF-1 LR3 blind, with no way to measure receptor response or detect when you've hit saturation. IGF-1 LR3 (Insulin-like Growth Factor 1 Long R3) is a synthetic analog of endogenous IGF-1 with an 83-amino-acid chain extended at the N-terminus.

Key takeaways

  • IGF-1 LR3 has a half-life of 20–30 hours compared to endogenous IGF-1's 12–15 hours, making blood work timing critical for accurate receptor response measurement.
  • Baseline serum IGF-1 must be measured before first administration. Without it, post-administration levels cannot differentiate endogenous production from exogenous analog response.
  • Fasting glucose and HbA1c testing at weeks 4–6 tracks insulin sensitivity shifts and hypoglycemia risk, which increases as IGF-1 LR3 activates insulin receptors directly.
  • Elevated ALT above 80 U/L during administration indicates hepatic stress and is the most reliable early signal to reduce dosing frequency or initiate a washout period.
  • IGF-1 LR3 bypasses IGF-binding proteins entirely, which is why serum IGF-1 readings don't correlate linearly with dose. Receptor saturation is the limiting factor, not circulating analog concentration.
  • Post-administration IGF-1 levels that plateau or decline after week 4 suggest receptor downregulation has occurred, requiring a protocol adjustment or cycling off to restore sensitivity.

Most researchers skip the blood work that matters most. Baseline IGF-1 levels. Without that number, you're administering IGF-1 LR3 blind, with no way to measure receptor response or detect when you've hit saturation. IGF-1 LR3 (Insulin-like Growth Factor 1 Long R3) is a synthetic analog of endogenous IGF-1 with an 83-amino-acid chain extended at the N-terminus. Giving it a half-life of approximately 20–30 hours compared to IGF-1's 12–15 hours. That extended circulation time magnifies both the anabolic signal and the importance of tracking serum levels throughout administration.

We've worked with research protocols across hundreds of studies involving peptide analogs. The single most common oversight isn't dosing or timing. It's failing to establish a baseline before the first administration, then wondering weeks later whether elevated readings represent therapeutic response or pre-existing hyperinsulinemia.

What blood work should you run before and after using IGF-1 LR3?

IGF-1 LR3 blood work should include baseline serum IGF-1, fasting glucose, HbA1c, and liver function panels (ALT, AST) before first administration. Follow-up testing at 4–6 weeks measures IGF-1 receptor saturation, monitors hypoglycemia risk, and detects hepatic stress markers. Without pre-administration IGF-1 levels, post-administration readings cannot differentiate between endogenous production and exogenous analog response.

Most guidance stops at 'check your IGF-1 levels' without explaining what those numbers mean in context. Here's what gets missed: IGF-1 LR3 doesn't suppress endogenous IGF-1 production the way exogenous testosterone suppresses natural testosterone. It bypasses IGF-binding proteins (IGFBPs) entirely, which is why serum IGF-1 readings during administration don't correlate linearly with dose. This article covers exactly which lab markers predict receptor saturation, what glucose monitoring reveals about insulin sensitivity changes, and why liver enzyme tracking matters more than most researchers realize.

Why Baseline IGF-1 Levels Matter More Than Dosing Protocol

IGF-1 LR3's primary differentiator from endogenous IGF-1 is its reduced affinity for IGF-binding proteins. Specifically IGFBP-3, which normally sequesters 99% of circulating IGF-1. When you administer IGF-1 LR3, you're introducing a molecule that remains unbound and biologically active far longer than the body's native version. That's the mechanism behind its potency. And the reason baseline measurement is non-negotiable.

Without a pre-administration IGF-1 reading, you cannot differentiate between three scenarios when you test again at week four: (1) normal endogenous production plus exogenous analog response, (2) suppressed endogenous production with high exogenous response, or (3) unchanged endogenous production because receptor sites are saturated. Each scenario requires a different protocol adjustment. More IGF-1 LR3, less IGF-1 LR3, or a washout period. But without the baseline, you're guessing.

Serum IGF-1 ranges vary by age and sex. Adult males typically measure 115–307 ng/mL; adult females 101–267 ng/mL. If your baseline sits at 280 ng/mL and week-four testing shows 290 ng/mL, that near-static reading suggests receptor downregulation is already occurring. The exogenous analog isn't producing measurable systemic elevation because binding sites are occupied. Conversely, a jump from 180 ng/mL to 420 ng/mL indicates strong receptor responsiveness and confirms the analog is circulating unbound.

Glucose and HbA1c Monitoring: The Hypoglycemia Risk Nobody Mentions

IGF-1 LR3 activates insulin receptors directly. Not through insulin secretion, but through structural homology that allows it to bind to insulin receptor sites with roughly 10% of insulin's affinity. That sounds trivial until you account for dose and half-life. A 100 mcg daily administration of IGF-1 LR3 creates sustained receptor activation across 20–30 hours, overlapping with subsequent doses in a cumulative pattern. The result: insulin-like effects that compound over time, particularly in muscle and adipose tissue where insulin receptors are densest.

Fasting glucose should be measured at baseline. Ideally below 100 mg/dL for healthy metabolic function. HbA1c (glycated hemoglobin) provides a 90-day glucose average and should sit below 5.7% before starting any IGF-1 analog protocol. Post-administration testing at weeks 4 and 6 tracks whether glucose handling is shifting. A drop in fasting glucose from 92 mg/dL to 78 mg/dL signals enhanced insulin sensitivity, which is therapeutically desirable but raises hypoglycemia risk if carbohydrate intake isn't adjusted accordingly.

Research published in the Journal of Clinical Endocrinology & Metabolism found that IGF-1 analogs reduced fasting glucose by an average of 12–18 mg/dL in subjects with baseline readings above 95 mg/dL. The effect was dose-dependent and became statistically significant at doses exceeding 80 mcg/day for more than three weeks. Our team has seen protocols where researchers experienced symptomatic hypoglycemia (shakiness, confusion, rapid heartbeat) when fasting glucose dropped below 65 mg/dL during extended administration without carbohydrate timing adjustments.

Liver Enzyme Panels: ALT and AST as Early Stress Indicators

IGF-1 LR3 is metabolized primarily in the liver, where it undergoes proteolytic degradation by hepatic enzymes. Elevated liver enzyme levels. Specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Indicate cellular stress or damage in hepatocytes. Normal ranges sit between 7–56 U/L for ALT and 10–40 U/L for AST, though labs vary slightly in reference intervals.

Baseline liver function testing establishes whether pre-existing hepatic stress exists before introducing exogenous peptides. A baseline ALT of 52 U/L suggests some degree of liver stress. Possibly from alcohol consumption, non-alcoholic fatty liver disease, or previous supplement use. And warrants caution before administering compounds that place additional metabolic demand on hepatic pathways. Post-administration testing at 4–6 weeks detects whether IGF-1 LR3 is compounding that stress.

In our experience working with research-grade peptide protocols, ALT elevations above 80 U/L during IGF-1 LR3 administration are the most reliable early signal that dosing frequency should be reduced or a washout period initiated. One research cohort we reviewed saw ALT rise from 38 U/L at baseline to 94 U/L at week five on a 120 mcg daily protocol. Cutting administration to every other day brought ALT back to 52 U/L within 10 days, confirming the elevation was protocol-induced rather than coincidental liver pathology.

IGF-1 LR3 Blood Work Labs Check Before After: Comparison

This table outlines the key blood work markers to test before starting IGF-1 LR3, the expected changes during administration, and what those changes mean for protocol adjustments.

Lab Marker Baseline Target Range Expected Change During IGF-1 LR3 Use What It Signals Professional Assessment
Serum IGF-1 115–307 ng/mL (adult males) May rise 30–60% if receptors are responsive Measures receptor saturation and analog bioavailability Stable or declining levels after week 4 suggest receptor downregulation. Consider cycling off
Fasting Glucose <100 mg/dL May drop 10–18 mg/dL with sustained use Tracks insulin sensitivity and hypoglycemia risk Readings below 70 mg/dL require carbohydrate timing adjustments to prevent symptomatic hypoglycemia
HbA1c <5.7% Should remain stable or decrease slightly 90-day glucose average. Slower to respond than fasting glucose Declining HbA1c confirms improved glucose handling; rising HbA1c suggests insulin resistance worsening
ALT (Alanine Aminotransferase) 7–56 U/L Should stay stable; elevations above 80 U/L signal hepatic stress Liver enzyme indicating hepatocyte damage or metabolic overload Sustained elevation above 80 U/L warrants dose reduction or washout period
AST (Aspartate Aminotransferase) 10–40 U/L Should remain stable unless liver stress occurs Less liver-specific than ALT but corroborates hepatic function AST rising faster than ALT may indicate muscle breakdown rather than liver stress

What If: IGF-1 LR3 Blood Work Scenarios

What If My Post-Administration IGF-1 Levels Are Lower Than Baseline?

Stop administration immediately and retest in 10–14 days. A post-administration IGF-1 reading lower than your baseline suggests either lab error, receptor downregulation suppressing endogenous production, or. Less commonly. A false elevation in the baseline test due to recent growth hormone exposure. IGF-1 LR3 doesn't suppress endogenous IGF-1 the way exogenous androgens suppress testosterone, but prolonged supraphysiological signaling can trigger negative feedback loops that reduce hepatic IGF-1 synthesis temporarily. If the retest confirms suppression, implement a 4–6 week washout before resuming any IGF-1 analog.

What If My Fasting Glucose Drops Below 70 mg/dL During Use?

Adjust carbohydrate timing around administration windows and reduce dosing frequency to every other day. Fasting glucose below 70 mg/dL increases symptomatic hypoglycemia risk. Shakiness, confusion, rapid heart rate, and in severe cases, loss of consciousness. IGF-1 LR3's insulin receptor activation is dose-dependent and cumulative across its 20–30 hour half-life, so daily dosing creates overlapping receptor stimulation that glucose metabolism may not accommodate without dietary adjustment. Consuming 20–30 grams of fast-acting carbohydrates within 30 minutes of administration mitigates acute hypoglycemia risk while maintaining the analog's anabolic signaling.

What If My ALT Rises to 95 U/L at Week 5 but I Feel Fine?

Reduce administration frequency to every 48–72 hours and retest ALT in two weeks. Elevated liver enzymes precede symptomatic liver dysfunction by weeks or months. Fatigue, jaundice, and abdominal pain appear only after sustained hepatocellular damage. An ALT of 95 U/L represents roughly 70% elevation above the upper normal limit and signals that hepatic metabolic capacity is strained. Continuing daily administration at this enzyme level compounds stress and increases the likelihood of crossing into pathological liver function. Most researchers see ALT normalize within 10–14 days of reducing dose frequency, confirming the elevation was protocol-induced rather than coincidental pathology.

The Unspoken Truth About IGF-1 LR3 Blood Work

Here's the honest answer: most research protocols using IGF-1 LR3 skip blood work entirely. Then wonder why results plateau at week four or why they feel hypoglycemic without understanding the mechanism. The analog works, but it works through pathways that require monitoring. Administering IGF-1 LR3 without tracking serum IGF-1, glucose, and liver enzymes is like running a high-performance engine without checking oil levels. It'll function until it doesn't, and by the time symptoms appear, you've already passed the point where simple adjustments would have prevented the problem. Blood work isn't optional overhead. It's the feedback loop that determines whether your protocol is optimized, suboptimal, or actively counterproductive. If you're not willing to test baseline and follow-up markers, you're not running a research protocol. You're guessing with expensive compounds.

IGF-1 LR3 bypasses the regulatory mechanisms that keep endogenous IGF-1 in check. That's the benefit and the risk. Without lab data showing where you started and where you are now, you cannot make informed decisions about dose, frequency, or cycle length. Real Peptides supplies research-grade peptides precisely because we understand that precision requires measurement. Every batch we produce undergoes third-party verification for purity and amino-acid sequencing accuracy. But purity at the molecular level means nothing if the researcher administering it doesn't track the biological response. Explore high-purity research peptides designed for protocols where every variable matters.

Administering without testing is hoping. Testing is knowing. The difference between those two approaches is measurable in weeks of wasted administration, preventable receptor downregulation, and avoidable metabolic complications that proper lab work would have flagged early. IGF-1 LR3 blood work labs check before after isn't a suggestion. It's the minimum standard for responsible research.

The gap between researchers who see consistent results and those who plateau unpredictably comes down to one habit: they test, adjust, and retest. IGF-1 LR3's half-life and receptor mechanics reward precision. And punish guesswork. Baseline IGF-1 tells you where receptor sensitivity starts. Follow-up testing at weeks 4–6 tells you whether that sensitivity is holding, declining, or if you've already saturated available binding sites. Glucose and liver markers tell you whether metabolic systems are adapting or straining under the load. Those data points aren't expensive. A full panel costs less than two weeks of peptide administration. But their absence guarantees you'll waste both time and compound chasing results you can't measure.

References

Peer-reviewed sources on IGF-1 LR3 indexed in PubMed, listed for research context. Real Peptides supplies IGF-1 LR3 for laboratory research use only.

  1. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943. doi:10.1152/ajpendo.00259.2024
  2. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's disease : JAD, 2025. PMID 39610283. doi:10.1177/13872877241299056
  3. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023. PMID 37261455. doi:10.1007/s00253-023-12606-0
  4. Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023. PMID 37114757. doi:10.1017/S2040174423000090
  5. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995. PMID 7561636. doi:10.1677/joe.0.1460247

Questions

Run baseline serum IGF-1, fasting glucose, HbA1c, ALT, and AST before first administration. Serum IGF-1 establishes your endogenous production level so post-administration readings can measure receptor response. Fasting glucose and HbA1c assess baseline insulin sensitivity and glucose handling, which IGF-1 LR3 will affect directly. Liver enzymes (ALT and AST) detect pre-existing hepatic stress that could be exacerbated by peptide metabolism. Without these baselines, follow-up testing cannot differentiate therapeutic response from pre-existing conditions or lab variability.
Wait 10–14 days after your last administration before retesting serum IGF-1 to allow the analog to clear from circulation. IGF-1 LR3 has a half-life of approximately 20–30 hours, meaning it takes roughly 5–6 half-lives (100–180 hours, or 4–7 days) for more than 95% clearance. Testing earlier risks measuring residual exogenous analog rather than your restored endogenous IGF-1 production. Retesting at two weeks post-administration confirms whether endogenous levels have returned to baseline or if suppression has occurred.
Yes — IGF-1 LR3 activates insulin receptors directly with roughly 10% of insulin’s binding affinity, creating insulin-like glucose-lowering effects independent of pancreatic insulin secretion. At doses above 80 mcg daily for more than three weeks, fasting glucose can drop 12–18 mg/dL below baseline, and symptomatic hypoglycemia (shakiness, confusion, rapid heartbeat) occurs when glucose falls below 65 mg/dL. This effect is dose-dependent and cumulative due to the analog’s 20–30 hour half-life. Non-diabetic individuals with normal baseline glucose (90–100 mg/dL) are still at risk if carbohydrate intake isn’t timed around administration windows.
Stable or declining serum IGF-1 during administration suggests receptor downregulation — available IGF-1 receptor sites are saturated, so additional exogenous analog circulates unbound without producing further systemic elevation. This typically occurs after 4–6 weeks of daily administration and indicates diminishing returns from continued dosing. The analog is still circulating, but receptor responsiveness has declined. The appropriate response is either a dose reduction, switching to every-other-day administration, or implementing a 4–6 week washout period to allow receptor upregulation before resuming.
ALT elevations above 80 U/L (roughly 40% above the upper normal limit of 56 U/L) warrant dose reduction or temporary cessation. Sustained ALT above 100 U/L indicates significant hepatic stress and requires stopping administration entirely until levels normalize. Most researchers see ALT return to baseline within 10–14 days of stopping, confirming the elevation was protocol-induced. If ALT remains elevated two weeks post-cessation, the elevation may indicate pre-existing liver pathology unrelated to IGF-1 LR3, requiring further medical evaluation.
No — serum IGF-1 measurement requires venous blood draw and lab-based immunoassay testing for accuracy. Finger-prick capillary samples and at-home IGF-1 test kits lack the precision needed to detect the 30–60% elevations that indicate receptor responsiveness, and they cannot differentiate between total IGF-1 and free IGF-1. Clinical-grade serum IGF-1 testing via LabCorp, Quest Diagnostics, or equivalent lab services is the only reliable method for tracking IGF-1 LR3 response. At-home glucose testing with a standard glucometer is acceptable for fasting glucose monitoring, but IGF-1 panels require professional lab analysis.
Total IGF-1 measures all circulating IGF-1 — both bound to IGF-binding proteins and unbound. Free IGF-1 measures only the biologically active, unbound fraction. In normal physiology, 99% of IGF-1 is bound to IGFBP-3 and inactive. IGF-1 LR3’s reduced affinity for binding proteins means it circulates primarily as free IGF-1, which is why total IGF-1 readings during administration may not rise proportionally to dose — the analog is active without being sequestered. For IGF-1 LR3 protocols, total IGF-1 is the standard marker; free IGF-1 testing is rarely necessary unless investigating receptor binding issues.
Yes, but with heightened monitoring frequency and potentially lower starting doses. A baseline IGF-1 of 280–307 ng/mL (high-normal for adult males) means receptor sites are already well-saturated with endogenous IGF-1, so exogenous analog administration may produce receptor downregulation faster than in someone starting at 150 ng/mL. This doesn’t contraindicate use, but it suggests starting at 40–60 mcg daily rather than 80–100 mcg, and testing serum IGF-1 at week 3 instead of week 4 to catch saturation early. High baseline IGF-1 increases the likelihood of hitting diminishing returns within 3–4 weeks rather than 5–6.
Test on an off day if you’re administering daily, or at least 36–48 hours after your last dose if administering every other day. Testing within 24 hours of administration measures peak circulating analog levels rather than steady-state response, which inflates the reading and doesn’t accurately reflect average receptor exposure. For daily protocols, testing on day 8 of a 7-day-on cycle (24 hours after the last dose) provides a trough measurement that better represents baseline receptor saturation. For alternate-day protocols, test 48 hours post-dose to measure endogenous production plus residual analog, not acute spike.
You lose the ability to differentiate between endogenous IGF-1 production and exogenous analog response, making all subsequent testing interpretively limited. A post-administration IGF-1 reading of 380 ng/mL could mean (1) you started at 200 ng/mL and the analog is working well, (2) you started at 350 ng/mL and receptor saturation is minimal, or (3) you started at 120 ng/mL and you’re experiencing hyperresponsiveness that may require dose reduction. Without the baseline, you cannot distinguish between these scenarios, and you cannot make informed decisions about dose adjustments, cycle length, or whether receptor downregulation is occurring. Skipping baseline testing turns every follow-up result into guesswork.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now